Tumor Surveillance: How Tumors May Resist Macrophage-Mediated Host Defense
- 12 January 1979
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 203 (4376) , 179-182
- https://doi.org/10.1126/science.758686
Abstract
Both normal human serum and supernatant from explanted malignant tumors contained a heat-stable low-molecular-weight factor that inhibited monocyte activation in vitro. In contrast, serum from individuals with solid tumors enhanced monocyte activation. It is suggested that the systemic activation of monocytes that occurs in malignant disease may be an appropriate host response but that successful tumors may continue to grow because they subvert the normal physiological signal for inhibition of macrophage activation.This publication has 35 references indexed in Scilit:
- Macrophage activation: increased ingestion of IgG-coated erythrocytes after administration of interferon inducers to mice.The Journal of Experimental Medicine, 1978
- Human migration inhibitory factor: purification and immunochemical characterization.The Journal of Experimental Medicine, 1978
- Altered expression of human monocyte Fc receptors in malignant diseaseNature, 1977
- An Inhibitor of Macrophage Chemotaxis Produced by NeoplasmsScience, 1976
- The Wiskott-Aldrich syndrome. Immunologic studies in nine patients and selected family membersCellular Immunology, 1975
- Modulation of macrophage Fc receptor expression in vitro by insulin and cyclic nucleotidesNature, 1975
- ABNORMALITIES OF LEUKOCYTE CHEMOTAXIS IN HUMAN DISEASE*Annals of the New York Academy of Sciences, 1975
- Macrophage Nonimmunologic Recognition: Target Cell Factors Related to Contact InhibitionScience, 1973
- Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytesCellular Immunology, 1972
- MACROPHAGES IN SYNGENEIC ANIMAL TUMOURSTransplantation, 1972